Details of the Drug

General Information of Drug (ID: DMOHT5V)

Drug Name
DKN-01
Indication
Disease Entry ICD 11 Status REF
Biliary tract cancer 2C17 Phase 2 [1]
Endometrial cancer 2C76 Phase 2 [2]
Esophageal cancer 2B70 Phase 2 [1]
Ovarian cancer 2C73 Phase 2 [2]
Cholangiocarcinoma 2C12.10 Phase 1/2 [3]
Multiple myeloma 2A83 Phase 1/2 [4]
Oesophagogastric junction cancer 2B71.Z Phase 1/2 [2]
Prostate cancer 2C82.0 Phase 1/2 [5]
⏷ Show the Full List of Indication(s)
Drug Type
Antibody
Cross-matching ID
TTD ID
DMF73Z
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dickkopf-related protein 1 (DKK1) TTE3RAC DKK1_HUMAN Inhibitor [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03818997) Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01711671) A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT03837353) A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. U.S. National Institutes of Health.
6 The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644.